| DB ID | MyCo_3808 |
| Title | Iranian patients co-infected with COVID-19 and mucormycosis: the most common predisposing factor, clinical outcomes, laboratory markers and diagnosis, and drug therapies |
| Year | 2022 |
| PMID | 35389322 |
| Fungal Diseases involved | Mucormycosis |
| Associated Medical Condition | COVID-19 patients |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The performed study’s protocol was approved by the Ethics Committee of Baqiyatallah University of Medical Sciences (Tehran, Iran) with an ethical code of IR.BMSU.REC.1399.536. Verbal and written informed consent from all the patients was obtained before performing this research. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | biopsy |
| Sample source | Homogenized Lungs tissue |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Corticosteroids |
| Biomarker Full Name | Corticosteroids |
| Biomarker Type | Diagnostic |
| Biomolecule | Hormone |
| Geographical Location | Iran |
| Cohort | A case-series analysis with a total of 10 patients with COVID-19 and mucormycosis coinfection (2 men and 8 women) using a census sampling were detected and admitted in special ward‘COVID-19 Patients’ of Baqiyatallah hospital (Tehran, Iran) from 12 March 2020 to 30 October 2020. |
| Cohort No. | 10 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Mucormycosis is an infectious disease caused by a class of filamentous moulds belonging to the orders Mucorales and Entomophthorales. This fungal infection is developed by inoculating spores into disrupted skin or wounds and their inhalation into the nares or lungs, as well as the ingestion of spoiled food materials. The incidence rate of mucormycosis is between 0.005 and 1.7 per million population, while the global fatality rate related to mucormycosis is 46%. Mucormycosis has a serious health concern as it is invasive and frequently fatal in susceptible patients who mostly have an immunocompromising predisposing condition such as diabetes (48%) or a previous transplantation history (22%). Moreover, this disease is so difficult to diagnose and its fatality rate doubles with a 6 day delay in the diagnosis and treatment. There are several case reports/series of COVID-19 and mucor- mycosis co-infection all around the world, each of them reported information about clinical and para-clinical manifestations of mucormycosis in the COVID-19 context. |
| Technique | CT scan |
| Analysis Method | High-resolution computed tomography (HR-CT) scans |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | High-resolution computed tomography (HR-CT) scans, laryngological or ophthalmological examination, qRT-PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
